



Aldeyra Therapeutics to Participate in Upcoming Investor Conferences

August 28, 2019

LEXINGTON, Mass.--(BUSINESS WIRE)--Aug. 28, 2019-- Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases, today announced that Todd C. Brady, M.D., Ph.D., President and CEO of Aldeyra, will participate in the following investor conferences in September:

- **Citi's 14th Annual Biotech Conference**
Four Seasons Hotel
Boston, Mass.
Thursday, September 5, 2019
- **BioCentury 26th Annual NewsMakers in the Biotech Industry**
Millennium Times Square New York
New York, N.Y.
Friday, September 6, 2019
- **3rd Annual Janney Healthcare Conference**
The Union League Club
New York, N.Y.
Monday, September 9, 2019
Presentation time: 11:50 a.m. ET

The Janney presentation will be webcast live and archived on the "Investors" section of the Aldeyra website, <http://ir.aldeyra.com/>.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a biotechnology company devoted to developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated diseases. Aldeyra's lead investigational drug product candidates are first-in-class potential treatments in development for dry eye disease, allergic conjunctivitis, proliferative vitreoretinopathy, and Sjögren-Larsson Syndrome. The company is also developing other product candidates for retinal and systemic inflammatory diseases.

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190828005400/en/>

Source: Aldeyra Therapeutics, Inc.

Corporate Contact:

David McMullin
Aldeyra Therapeutics, Inc.
Tel: 781-761-4904 ext. 218
dmcullin@aldeyra.com

Investor & Media Contact:

Scott Solomon
Sharon Merrill Associates, Inc.
Tel: 617-542-5300
ALDX@investorrelations.com